Navigation Links
New Report by BioTrends Research Group to Highlight the Launch of ULORIC(R) (febuxostat)
Date:2/24/2009

EXTON, Pa., Feb. 24 /PRNewswire/ -- BioTrends is pleased to announce the fielding of a new syndicated report, LaunchTrends(TM): Uloric(R). Takeda Pharmaceutical Company Limited announced that they received FDA approval for Uloric(R) (generic name: febuxostat) on February 13, 2009. Uloric(R) is indicated for the chronic management of hyperuricemia associated with gout and represents the first product for gout that has been approved in over forty years.

LaunchTrends(TM): Uloric(R) is a three wave primary market research study that consists of a quantitative on-line survey and qualitative telephone interviews. In total, 300 Rheumatologists and Primary Care Physicians will participate in the research. Following a baseline report, three additional waves will be published capturing launch effectiveness at one month, three months, and six months post launch. The reports are designed to assess trial and use of Uloric(R), obstacles to use, typical patient types, product perceptions, promotional efforts/messages, and satisfaction with the product relative to other agents.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
2. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
3. Video: Zometa(R) Reduces Risk of Breast Cancer Recurrence in Premenopausal Women, Study in The New England Journal of Medicine Reports
4. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
5. Blue Light Destroys Antibiotic-Resistant Staph Infection - Results Reported in Photomedicine and Laser Surgery Journal
6. MannKind Reports Successful Completion of Device Bioequivalence Trial
7. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Pharmasset Reports Fiscal Year End 2008 Financial Results
10. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
11. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... HASTINGS ON HUDSON, N.Y. , Dec. 6, ... anxiety, there,s now a reason to be hopeful. ... the way to a less anxious life. ... Robert Buck, the psychotherapist ... they represent a breakthrough approach to overcoming anxiety ...
(Date:12/5/2016)... , Dec. 5, 2016  Balloon catheter is an ... is inserted into the femoral artery in the leg ... to treat constricted blood vessels. These products are generally ... atherosclerosis – deposition of lipid substances in the blood ... market is projected to expand at a CAGR of ...
(Date:12/5/2016)... WARSAW, Ind. , Dec. 5, 2016  Zimmer ... "Company") today announced that, pursuant to its previously-announced ... securities identified in the table below (collectively, the ... Notes were validly tendered and not validly withdrawn ... York City time, today, December 5, ...
Breaking Medicine Technology:
(Date:12/6/2016)... CA (PRWEB) , ... December 06, 2016 , ... The ... with the Teddy Bear Cancer Foundation (TBCF), a nonprofit 501(C)(3) organization providing ... Ventura and San Luis Obispo counties. To assist TBCF, the NALA recently hosted a ...
(Date:12/6/2016)... ... December 06, 2016 , ... Public middle ... 15, 2017 to apply for a 2016/2017 California Casualty Thomas R. Brown Athletics ... Qualifying schools can receive up to $3,000. , The grant is named ...
(Date:12/6/2016)... ... December 06, 2016 , ... Healthcare leaders ... healthcare regulations at the 7th annual Health IT Leadership Summit, to be held ... administrator for the Centers for Medicare & Medicaid Services (CMS), will be the ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... with an Award of Distinction, recognizing the organization as a top behavioral service ... in the areas of clinical quality, staff satisfaction and qualifications, and consumer satisfaction. ...
(Date:12/6/2016)... ... December 06, 2016 , ... United ... to announce it has added CXC Solutions (CXC) as a new Strategic Partner. ... solutions are tailored to help benefits advisors reduce operating costs and generate additional ...
Breaking Medicine News(10 mins):